- Home
- TRN vs ACAD Comparison
TRN vs ACAD Comparison
Compare TRN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRN
- ACAD
- Stock Information
- Founded
- TRN 1933
- ACAD 1993
- Country
- TRN United States
- ACAD United States
- Employees
- TRN N/A
- ACAD N/A
- Industry
- TRN Railroads
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- TRN Industrials
- ACAD Health Care
- Exchange
- TRN Nasdaq
- ACAD Nasdaq
- Market Cap
- TRN 2.3B
- ACAD 3.8B
- IPO Year
- TRN N/A
- ACAD 2004
- Fundamental
- Price
- TRN $27.64
- ACAD $21.89
- Analyst Decision
- TRN Hold
- ACAD Buy
- Analyst Count
- TRN 1
- ACAD 18
- Target Price
- TRN $24.00
- ACAD $27.71
- AVG Volume (30 Days)
- TRN 793.2K
- ACAD 2.0M
- Earning Date
- TRN 07-31-2025
- ACAD 08-05-2025
- Dividend Yield
- TRN 4.35%
- ACAD N/A
- EPS Growth
- TRN 8.99
- ACAD N/A
- EPS
- TRN 1.63
- ACAD 1.37
- Revenue
- TRN $2,855,000,000.00
- ACAD $996,283,000.00
- Revenue This Year
- TRN N/A
- ACAD $13.39
- Revenue Next Year
- TRN $6.29
- ACAD $10.59
- P/E Ratio
- TRN $16.93
- ACAD $15.73
- Revenue Growth
- TRN N/A
- ACAD 22.42
- 52 Week Low
- TRN $23.01
- ACAD $13.40
- 52 Week High
- TRN $39.83
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- TRN 54.90
- ACAD 54.40
- Support Level
- TRN $27.62
- ACAD $20.75
- Resistance Level
- TRN $29.29
- ACAD $22.14
- Average True Range (ATR)
- TRN 0.58
- ACAD 0.78
- MACD
- TRN 0.02
- ACAD -0.14
- Stochastic Oscillator
- TRN 49.03
- ACAD 48.72
About TRN Trinity Industries Inc.
Trinity Industries Inc. sells and leases railroad products and railcar maintenance services in North America. The company operates under the name TrinityRail in three main segments: railcar leasing and management services, which owns railcars and provides fleet management and administration services; rail products, which builds, sells, and modifies freight and tank railcars and their components; and all other, which sells highway products such as guardrail and other highway barriers. Customers include railroads, leasing companies, and shipping companies in agriculture, construction, consumer products, energy, and chemicals.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.